ThioBridge(TM) linker to attach cytotoxic payloads to alpha fetoprotein
ACT has developed a novel drug delivery system based on AFP, a shuttle protein that binds to AFP receptors, which are present in large amounts on the majority of cancer cells but only rarely on healthy cells. AFP has been studied extensively and has been shown to be safe in Phase I and II clinical studies involving over 400 patients. ACT's lead product (ACT-901), which is in preclinical development, will use AFP initially to deliver paclitaxel to ovarian tumours.
PolyTherics has developed ThioBridge(TM) for site-specific conjugation of cytotoxic payloads to disulfide bonds in proteins and antibodies to provide more stable and less heterogeneous drug conjugates. Under the collaboration PolyTherics will conjugate AFP to a derivative of a known cytotoxic drug using ThioBridge(TM) to produce a range of different drug conjugates for testing.
PolyTherics is a wholly owned subsidiary of
PolyTherics specializes in proprietary site-specific conjugation technologies for antibody drug conjugate development (ThioBridge(TM)) and solutions for optimization of the therapeutic properties of biopharmaceuticals (TheraPEG(TM), CyPEG(TM), HiPEG(TM) and PolyPEG(TM)).
Abzena is the new name for the PolyTherics group, and is focused on providing proprietary technologies and value-added services to enable the development of better biopharmaceuticals.
Abzena comprises two wholly owned subsidiary businesses - PolyTherics and Antitope - which have established a broad suite of complementary technologies that are designed to improve the chances of successful development of antibodies and proteins with enhanced therapeutic benefits.
Antitope is an industry leader in immunogenicity assessment, protein engineering for creating humanized antibodies and deimmunised therapeutic proteins, and cell line development for manufacture.
The group has built a global customer base over the past decade, including the top 10 pharma, large and small biotech, and academic groups.
Abzena is a privately owned
About Alpha Cancer Technologies
ACT is a drug delivery company with an innovative targeted chemotherapy delivery platform for the treatment of cancer. ACT uses recombinant human alpha-fetoprotein to selectively target cancer cells by delivering toxic chemotherapeutic agents exclusively to these cells. This approach offers the benefits of much lower toxicity and greater efficacy compared to conventional chemotherapy.
ACT is a private Canadian company based in
For more information, please contact: